NCT01983501View on ClinicalTrials.gov

A Study of Tucatinib (ONT-380) Combined With Ado-trastuzumab Emtansine (T-DM1) in Patients With HER2+ Breast Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

57

Participants

Timeline

Start Date

February 28, 2014

Primary Completion Date

October 10, 2017

Study Completion Date

September 3, 2020

Conditions
HER2 Positive Breast Cancers
Interventions
DRUG

Tucatinib (ONT-380)

Given twice per day, orally

DRUG

T-DM1

Given intravenously once every 21 days

Trial Locations (11)

35294

University of Alabama, Birmingham

37203

Sarah Cannon Research Institute, Nashville

66160

University of Kansas, Kansas City

80045

University of Colorado Cancer Center, Aurora

97213

Providence Cancer Center, Portland

98045

Northwest Medical Specialties, Tacoma

02215

Dana Farber Cancer Institute, Boston

N6A 5W9

London Health Sciences Centre, London

M5T 2M9

Princess Margaret Cancer Centre, Toronto

H7M 3L9

Hospital de la Cite-de-la-Sante, Laval

H3T 1E2

Jewish General Hospital, Montreal

All Listed Sponsors
lead

Seagen Inc.

INDUSTRY

NCT01983501 - A Study of Tucatinib (ONT-380) Combined With Ado-trastuzumab Emtansine (T-DM1) in Patients With HER2+ Breast Cancer | Biotech Hunter | Biotech Hunter